DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

01875 TOT BIOPHARM-B

Trading Add to Porfolio
Index Constituent : None
Major Shareholders Center Laboratories, Inc. (28.59%)
Suzhou Vivo Management Consulting Partnership (Limited Partnership) (15.04%)
Vivo Capital LLC (13.36%)
Chengwei Evergreen Capital, L.P. (7.32%)
Advantech Capital L.P. (6.36%)
Tricor Trust (Hong Kong) Limited (5.05%)		 Sector Health Care & Biotechnology
Web Site http://www.totbiopharm.com.cn Tel (86 512) 6296-5186
Email ir@totbiopharm.com Fax (86 512) 6296-5286
Related Equities N/A
Principal Activities The Company is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies. With rich practical experience and a mature technology platform and quality system, we provide one-stop CDMO solutions for drug development and production.

Consolidated List of Substantial Shareholders

Name Number of Shares Interested % of Issued Share Capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool

Complete List of Directors

Director's Name Number of Shares Interested % of issued share capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool
Back to Top